50% of Pharmaceutical Companies Employ Dedicated Counter-Generics Teams
Of Top 10 and 50 pharma companies, 75% use a dedicated counter-generics structure.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nearly 75% of surveyed Top 10 and Top 50 pharmaceutical companies use a dedicated counter-generics team structure, revealed a Cutting Edge Information study.
“Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion”
Counter-generics teams, whether dedicated to the task or created as-needed for each project, are necessary for any pharmaceutical company facing a product’s patent expiration. The study, “Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” found that over half of all surveyed companies maintain a dedicated structure for counter-generics planning and implementation.
Small companies surveyed, of which only 39% report a dedicated counter-generics team, skew the overall data. Small companies most likely do not have the infrastructure in place to the same degree as larger companies, which may be the reason for their lack of dedicated teams.
“While some companies do not maintain dedicated counter-generics groups, they often follow similar principles as those companies that maintain dedicated groups when planning and implementing counter-generics strategies,” said David Richardson, research manager at Cutting Edge Information. “Drug manufacturers both with and without dedicated teams leverage similar internal expertise to drive counter-generics strategy creation and implementation.”
The report shows that product or brand management teams are almost always involved with counter-generics planning in companies with no dedicated team. Patent expiration management strategies often stem from brand teams’ concerns about retaining profit after the product’s loss of exclusivity. These concerns, combined with the team’s product knowledge, make that department’s involvement almost mandatory wherever the function exists. Brand teams are also the only function involved with counter-generics in more than half of all companies that do not have dedicated teams or create ad hoc teams for individual products.
“Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” (http://www.cuttingedgeinfo.com/research/portfolio-management/counter-generics/) profiles more than 15 counter-generics strategies, team structures and staffing, and includes 39 case studies of companies’ approaches to combating generics.
Use this report to:
- Plan for and implement a diverse and robust set of strategies.
- Build a strong counter-generics task force early.
- Prepare for emerging biosimilar competition and changing approval pathways.
For more information about Counter-Generics and Biosimilars, contact Cassie Demeter at 919-403-6583.